Sodium-dependent serotonin transporter (SLC6A4) extracellular allosteric site (SERT S2 site)

The extracellular allosteric site of the serotonin transporter (SLC6A4), commonly known as the S2 site, is a secondary binding pocket located within the extracellular vestibule of the transporter protein [4, 11]. While the primary orthosteric (S1) site is responsible for the binding and translocation of serotonin, the S2 site serves as a regulatory locus that can allosterically modulate the binding kinetics of ligands at the S1 site [1, 9]. Specifically, the binding of certain antidepressants, such as escitalopram and vilazodone, to the S2 site stabilizes the drug-transporter complex at the S1 site by sterically hindering the dissociation of the orthosteric ligand [2, 5]. This dual-binding mechanism results in a more potent and sustained inhibition of serotonin reuptake compared to drugs that only occupy the S1 site [3, 6]. The SLC6A4 protein is a critical therapeutic target for major depressive disorder, anxiety, and obsessive-compulsive disorder, and the allosteric site represents a key area for the development of next-generation antidepressants with improved efficacy profiles [10, 15]. Genetic polymorphisms, such as the 5-HTTLPR variant, further influence the expression and functional response of this target in clinical populations [12, 13].

Other names

S2 siteVestibular allosteric siteSLC6A4 allosteric siteExtracellular vestibule siteLow-affinity allosteric site

Allosteric modulation of the serotonin transporter (SLC6A4) by binding to the S2 site in the extracellular vestibule, which sterically hinders the dissociation of orthosteric ligands from the S1 site, thereby increasing the potency and duration of serotonin reuptake inhibition [1, 4, 11].